|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
Institute for Infectious Diseases of Animals, Justus Liebig University of Giessen, D-35392 Giessen, Germany
Address for correspondence: Judith Tyczka, Institute for Hygiene and Infectious Diseases of Animals, Justus Liebig University of Giessen, Frankfurter Str. 85-89, D-35392 Giessen, Germany. Voice: +49 641 9938308; fax: +49 641 9938309 judith.tyczka{at}vetmed.uni-giessen.de
Previous attempts to develop Q fever vaccines were less successful in that the vaccines caused unacceptable side effects or failed to be protective. In this study, we tested the efficacy of a mixture of eight recombinant Coxiella burnetii (C. b.) proteins in sublethal challenge infections with mice. Eight potential C. b. virulence genes (Omp, Pmm, HspB, Fbp, Orf410, Crc, CbMip, and MucZ) were overexpressed in E. coli as his-tagged fusion proteins and partially purified. All recombinant proteins but rPmm proved to be antigenic in BALB/c mice when administered as protein mixtures. For efficacy testing, mice were immunized with an adjuvanted mixture of the eight recombinant proteins and subsequently challenged intraperitoneally with the C. b. isolate Nine Mile RSA493 (1.8 x 108 C. b.). Only animals vaccinated with the licensed Q fever vaccine Q-VaxTM (vaccination control) exhibited milder symptoms and minor gain of spleen and liver weights. In summary, clinical examinations and dissection of mice immunized with the eight recombinant C. b. proteins did not indicate a protective immune response after test infection.
Key Words: Q fever • Coxiella burnetii • mice • vaccination • recombinant proteins • challenge • protection
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
